Results 71 to 80 of about 4,011 (178)

Treprostinil for pulmonary hypertension

Vascular Health and Risk Management, 2008
Nika Skoro-Sajer1, Irene Lang1, Robert Naeije21Division of Cardiology, Department of Internal Medicione II, Vienna General Hospital, Medical University of Vienna, Austria; 2Department of Cardiology, Erasme University Hospital, Brussels, BelgiumAbstract ...
Nika Skoro-Sajer, Irene Lang, Robert Naeije   +2 more
doaj  

Shared Decision‐Making During Pulmonary Arterial Hypertension Therapy Selection: A Patient and Clinician Survey

Pulmonary Circulation, Volume 16, Issue 3, July 2026.
ABSTRACT Selection of therapy for pulmonary arterial hypertension (PAH) requires tradeoffs among disease severity, therapeutic benefit, adverse effects, treatment burden, quality of life, and patient values. Although professional societies endorse shared decision‐making (SDM) in this context, empirical data describing SDM in PAH are limited.
Paresh C. Giri, Jeanette Merrill‐Henry, Tiffany Rajah, Donald R. Sullivan, Udochukwu Oyoyo, Katrina Barry, Jean M. Elwing, Vijay P. Balasubramanian   +7 more
wiley   +1 more source

Inhaled treprostinil sodium for pulmonary hypertension

, 2014
Introduction: Pulmonary arterial hypertension is an increasingly recognized heterogeneous disease with significant morbidity and mortality, requiring a multimodal approach to treatment.
Krasuski, RA, Gupta, V
core   +1 more source

Therapeutic Potential of Treprostinil Inhalation Powder for Patients with Pulmonary Arterial Hypertension: Evidence to Date [PDF]

Steven J Cassady,1 Jose Alejandro N Almario,2 Gautam V Ramani3 1Division of Pulmonary & Critical Care Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; 2Department of Internal Medicine, University of Maryland School of Medicine ...
Almario JAN, Cassady SJ, Ramani GV
core  

Rapid Switch From Intravenous Epoprostenol to Intravenous Treprostinil in Patients With Pulmonary Arterial Hypertension.

, 2007
Intravenous epoprostenol improves exercise capacity and survival in patients with pulmonary arterial hypertension (PAH); however, chemical instability and a short half-life have caused limitations in its use.
Paillette LD, Simonneau G, Davis G, Jais X, Sitbon O, PALAZZINI, MASSIMILIANO, MANES, ALESSANDRA, PRESOTTO, LUISA, Humbert M, Zaccardelli D, Jeffs R, GALIE', NAZZARENO   +11 more
core   +1 more source

Evidence for PDZ‐Binding Kinase in Lung Disease With an Emphasis on PAH

Pulmonary Circulation, Volume 16, Issue 3, July 2026.
ABSTRACT Originally named T‐cell‐originated Lymphokine‐activated killer protein kinase (TOPK), PDZ‐Binding Kinase (PBK) is a serine/threonine kinase that is a member of the family of mitogen‐activated protein kinases (MAPKKs), which is overexpressed in lung cancer and interstitial pulmonary fibrosis (IPF). Along these lines, recent work also shows that
Scott A. Barman, Zsuzsanna Bordan, David J. R. Fulton   +2 more
wiley   +1 more source

Comparative effectiveness of oral prostacyclin pathway drugs on hospitalization in patients with pulmonary hypertension in the United States: a retrospective database analysis

Pulmonary Circulation, 2020
Two oral medications targeting the prostacyclin pathway are available to treat pulmonary arterial hypertension in the United States: oral treprostinil and selexipag. We compared real-world hospitalization in patients receiving these medications.
John W. McConnell, Yuen Tsang, Janis Pruett, William Drake III   +3 more
doaj   +1 more source

Effectiveness of PAH Specific Treatment Is Comparable Between PAH Associated With Connective Tissue Disease and Idiopathic PAH: Data From the Multicentre National Registry

Pulmonary Circulation, Volume 16, Issue 3, July 2026.
ABSTRACT Pulmonary arterial hypertension (PAH) is a rare disease with poor prognosis. The same treatment is recommended in patients with PAH associated with connective tissue disease (CTD) and idiopathic PAH (IPAH). However, the effectiveness of PAH‐specific treatment in these both groups is inconsistent.
Anna Smukowska‐Gorynia, Sylwia Iwańczyk, Michał Ciurzyński, Marcin Waligóra, Marcin Kurzyna, Piotr Pruszczyk, Grzegorz Kopeć, Katarzyna Mizia‐Stec, Ilona Skoczylas, Łukasz Chrzanowski, Piotr Błaszczak, Katarzyna Ptaszyńska, Grzegorz Grześk, Ewa Malinowska, Małgorzata Peregud‐Pogorzelska, Michał Tomaszewski, Ewa Mroczek, Miłosz Jaguszewski, Ewa Lewicka, Katarzyna Widejko, Agnieszka Pawlak, Wojciech Jacheć, Zbigniew Gąsior, Katarzyna Betkier‐Lipińska, Judyta Winowska‐Józwa, Marta Banaszkiewicz, Tatiana Mularek‐Kubzdela   +26 more
wiley   +1 more source

Combination therapy with oral treprostinil for pulmonary arterial hypertension. a double-blind placebo-controlled clinical trial [PDF]

, 2020
Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hypertension (PAH), but the effect on clinical outcomes was unknown.
Park M. H., Kruger U., Sharma K. H., Eggert M. S., Fitzgerald J., Dwyer N. B., Chopra V., Chunde B., Williams T. J., Mehta J. P., Cheng X., Oomman A., Segel M. J., Srinivasa Sastry B. K., Chung W. -J., Held M., Wirtz H., Dromer C., Sawhney J. S., Song J. -M., Lordan J. L., Chen Y., Pulido T. R., Klose H., Rahaghi F. F., Rame J. E., Coghlan J. G., Koch A., Deng C. Q., Cajigas H., Zhu X., Carlsen J., Oudiz R. J., Tapson V. F., Nielsen-Kudsk J. E., Lescano A. J., Kim H. -K., Hage A., Reynaud-Gauber M., Ben-Dov I., Lang I. M., Schilz R., Halank M., Vonk M. C., Grunig E., Teik L. S., Yoo H., Hansdottir S., Hsu H. -H., Markin C. J., Allen R., Kerkar P. G., Steringer-Mascherbauer R., Brown M. R., Ewert R., Grover R., Corris P. A., Vizza C. D., Diez F. A., Elwing J., McDonough C., Miller C. E., Chang H. -J., Badesch D. B., Cheng Z., Mularek-Kubzdela T., Yang Y., Scelsi L., Boonstra A., Suresh P. V., Hiremath S., White R. J., Hauptmeier B. M., Liu J., Konstantinides S., Yu Z., Hachulla E., Li X., Feldman J. P., Huang W. -C., Allen S., Podolec P., Moreira M. C., Zwicke D. L., Seronde M. -F., Shen J., Zhang S., Park J. -B., Sepulveda P., Bimalendu S., Seeram V. K., Klinger J. R., Rajput R. K., Rischard F., Feenstra E., Arakaki J. O., Baxi H. A., Thompson A. B., Lapa M. S., Mehta S., Migliore C., Nissell M., Michelakis E., Sood N., Swiston J., Alnuaimat H., Argyropoulou-Pataka P., Edla Kumar P. K., Harvey W., Kermeen F. D., Smallwood D. M., Sobkowicz B., Grinnan D., Keogh A. M., Pulido T., Chaouat A., Bortman G. R., Wang K. Y., Yigla M., Hill N., Kronsbein J., Rundqvist B., Hsu C. -H., Mathier M., Jerjes-Sanchez C., Hua Y., Lange T. J., Cheng C. -C., Pepke-Zaba J. W., Franco V., Wang K. -Y., Yousseff P. P., Botta C. E., D'Alto M., Oren R. M., Torbicki A., Kiely D. G., Wilkens H., Campos F., Kim D. -K., Ng B. J. -H., Abhaichand R. K., Rosenkranz S., Cadaret L., Yip W. L. J., Orfanos S., De Souza R., Chang S. -A., Meyer G. M. B., De Amorim Correa R., Awdish R., Neurohr C., Hoffken G., Hjalmarsson C., Fisher M., Bourdin A., Pan L., Waxman A., Mehrotra R., Zhou D., Zagolin M., Zhang G., Balasubramanian V., Patel B., Hirani N., Qun Y., Vitulo P., Trichon B. H., Khan A., Svetliza G. N., Berkman N., Adir Y., Bajwa A., McConnell J. W., Kramer M. R.   +174 more
core   +1 more source

Comparison of hemodynamic responses to Treprostinil and postoperative outcomes in patients with pulmonary hypertension after Glenn or Fontan procedures

Medicine Plus
Background: To compare the hemodynamic effects of Treprostinil and postoperative outcomes in pediatric single-ventricle patients with pulmonary hypertension (PH, mean pulmonary artery pressure (mPAP) >15 mmHg) following Glenn or Fontan palliation, and ...
Xiaofeng Wang, Chenyu Li, Qinnan Chen, Shilin Wang, Zhiyuan Zhu, Xu Wang   +5 more
doaj   +1 more source